Terminated based on mutual agreement between PI and sponsor (Glaxo Smith Kline)

Fluticasone furoate is being studied to determine whether treatment with a topical nasal steroid, in patients with existing nasal polyps , can not only improve symptoms but also suppress the recurrence of clinically significant nasal polyp obstruction and prevent surgical intervention.

Inclusion Criteria:

1. Male and female patients 18-70 years of age, in general good health.
2. Current evidence of nasal polyps on physical exam. 3) Able to understand the protocol and comply with instructions. 4) Have a negative urine pregnancy test in women of childbearing potential. 5) Women of childbearing potential must be on an acceptable method of birth control or willing to remain abstinent through the duration of the study.

Exclusion Criteria:

1. Are pregnant and/or breast-feeding.

2. History of alcohol or drug abuse in the past year.

3. Signs and symptoms suggestive of fulminant bacterial sinusitis (fever >101 F, persistent severe unilateral facial or tooth pain, facial swelling).

4. Allergies to nasal corticosteroids

5. .Other chronic significant medical illnesses 6) Maintenance oral prednisone therapy for other chronic medical conditions.

   -

   -

The PI has left the institution and neither he, nor the data if any, is available. All information provided has been obtained from the Johns Hopkins University School of Medicine Institutional Review Board and was only available as one arm.

No data was collected/is available for the study as it was terminated prematurely and the PI has since left the institution. The information in Adverse events is presenter per arm, as the arm assignment, if any, is unknown.